Based on the aggregated intelligence of 160,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Exelixis (Nasdaq: EXEL) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Exelixis' business and see what CAPS investors are saying about the stock right now.

Exelixis facts

Headquarters (Founded)

South San Francisco, Calif. (1994)

Market Cap

$652 million

Industry

Biotechnology

Trailing-12-Month Revenue

$152 million

Management

CEO Dr. George Scangos (since 1996)

CFO Frank Karbe (since 2004)

Lead drug candidate

XL186 for various cancers including lung, thyroid, and brain, in phase 3 trials

Cash/Debt

$203 million / $80 million

Competitors

Array Biopharma (Nasdaq: ARRY)

Genzyme (Nasdaq: GENZ)

Onyx Pharmaceuticals (Nasdaq: ONXX)

Strategic Partners

Bristol-Myers Squibb (NYSE: BMY)

GlaxoSmithKline (NYSE: GSK)

sanofi-aventis (NYSE: SNY)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 97% of the 723 All-Star members who have rated Exelixis believe the stock will outperform the S&P 500 going forward. These bulls include TMFBreakerTAllan and zzlangerhans, both of whom are ranked in the top 3% of our community.

In a reply pitch from last week, TMFBreakerTAllan kept Fools up to speed on the company's recent strategy shift:

Big change in focus with [Exelixis] in the past few weeks. The company is now dedicating the bulk of its resources to three drug candidates that are in late phase testing. Only a year or so to see if the science will be prove to be correct in its approach to treat cancers. If successful, the wait will have been worth it for investors from the past few years.

In a pitch from three days later, zzlangerhans expands on the stock's recent weakness as an opportunity to pounce:

The current downward momentum was accelerated by the company's announcement of a 40% reduction in workforce and a restructuring of the pipeline to focus on partnered compounds. For longtime followers of Exelixis, that news is not unwelcome. Exelixis never had problems bringing new compounds into the pipeline, they've just been very slow to progress them. So hopefully a narrowing will be followed by a lengthening.

What do you think about Exelixis, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Exelixis is a Motley Fool Rule Breakers choice. The Fool owns shares of Exelixis and Glaxo. The Fool's disclosure policy always gets a perfect score.